Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: Comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 5, 2001, Pages 1287-1296

  Perez, Carlos A ^a,b   Michalski, Jeff M ^a   Lockett, Mary Ann ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Director Radiation Oncology Center   (United States)

Author keywords

Localized carcinoma of the prostate; Nadir prostate specific antigen

Indexed keywords

ANTIGENS; BIOCHEMISTRY; CARCINOGENS; HISTOLOGY; ONCOLOGY; THREE DIMENSIONAL;

PROSTATE;

RADIOLOGY;

PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; CORRELATION FUNCTION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MEDICAL RECORD; METASTASIS; ORGANIZATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIOGRAPHY; RECURRENT CANCER; TREATMENT FAILURE; TUMOR BIOPSY;

DISEASE-FREE SURVIVAL; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SOCIETIES, MEDICAL; TIME FACTORS;

EID: 0035312166     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01492-9     Document Type: Conference Paper

References (56)

1. Prostate
2. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3)
3. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate; Development of a system of patient selection
4. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
5. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
6. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
7. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer
8. The fall and rise of prostate-specific antigen; Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer
9. Linear regression analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer
10. Prostate-specific antigen doubling times in patients with prostate cancer; A potentially useful reflection of tumor doubling time
11. Consensus statement; Guidelines for PSA following radiation therapy
12. Pretreatment prostate-specific antigen doubling times; Clinical utility of this predictor of prostate cancer behavior
13. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy
14. Prostatic-specific antigen and external beam radiation therapy in prostatic cancer
15. Prostate specific antigen after external beam radiotherapy for prostatic cancer; Follow-up
16. Prostate specific antigen after irradiation for prostatic carcinoma
17. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer
18. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer
19. 125Iodine implantation for stage T1/T2 prostatic carcinoma
20. Brachytherapy for clinically localized prostate cancer; Results at 7- and 8-year follow-up
21. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation
22. An analysis of clinical and treatment related prognostic factors of outcome using biochemical control as an end-point in patients with prostate cancer treated with external beam irradiation
23. Maximum utilization of the life table method in analyzing survival
24. Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control; A comprehensive review of the literature
25. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer
26. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
27. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens
28. Radical radiation therapy in the management of prostatic adenocarcinoma; The initial PSA value as a predictor of treatment outcome
29. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate
30. Localized prostate cancer; Use of serial prostate-specific antigen measurements during radiation therapy
31. Serum prostatic specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy
32. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer
33. Prostate-specific antigen density; A new prognostic indicator for prostate cancer
34. Radiation therapy for T1 and T2 prostate cancer; Prostate-specific antigen and disease outcome
35. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
36. Natural history of progress after PSA elevation following radical prostatectomy
37. Predictors of distant metastasis 7 years after a rising PSA in prostate cancer patients treated with external beam radiotherapy
38. Current status of prostate-specific antigen in the radiotherapeutic management of prostatic cancer
39. The effect of pelvic radiation therapy on the production of prostatic specific antigen
40. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer
41. The treatment of prostate cancer by conventional radiation therapy; An analysis of long-term outcome
42. The value of serial prostate specific antigen determinations 5 years after radiotherapy; Steeply increasing values characterize 80% of patients
43. 501 Men irradiated for clinically localized prostate cancer (1987-1995); Preliminary analysis of the experience at UCSF and affiliated facilities
44. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
45. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer
46. Serum prostate-specific antigen profile following radiotherapy for prostate cancer; Implications for patterns of failure and definition of cure
47. A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy
48. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer
49. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
50. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
51. Radiation therapy for clinically localized prostate cancer; A multi-institutional pooled analysis
52. Changes in biochemical disease-free survival rates as a result of adoption of the Consensus Conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy
53. PSA relapse definitions; The Vancouver rules show superior predictive power (Letter to editor)